Loading...
Sarcopenia predicts short-term treatment-related toxicity in patients undergoing curative-intent therapy for head and neck cancer: A systematic review and meta-analysis
Mascarella, Marco A. Ferdus, Jannatul Vendra, Varun Sridharan, Shaum Sultanem, Khalil Tsien, Christina Shenouda, George Bouganim, Nathaniel Esfahani, Khashayar Richardson, Keith
Mascarella, Marco A.
Ferdus, Jannatul
Vendra, Varun
Sridharan, Shaum
Sultanem, Khalil
Tsien, Christina
Shenouda, George
Bouganim, Nathaniel
Esfahani, Khashayar
Richardson, Keith
Citations
Altmetric:
Genre
Journal article
Date
2024-02-14
Advisor
Committee member
Group
Department
Otolaryngology
Permanent link to this record
Collections
Files
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1002/hed.27688
Abstract
Sarcopenia is an increasingly recognized biomarker associated with poorer outcomes. The objective of this study was to ascertain the effect of sarcopenia on treatment tolerance and short-term toxicity in head and neck cancer (HNC). A systematic review was performed using multiple databases. An inverse-variation, random-effects model was used to perform the meta-analysis to evaluate the effect of sarcopenia on severe treatment toxicity and poor treatment tolerance. Sixteen observational studies, including 3187 patients with HNC, were analyzed. The combined odds ratio (OR) for severe treatment toxicity and tolerance was 2.22 (95%CI 1.50–3.29) and 1.40 (95%CI 0.84–2.32), respectively. The effect of sarcopenia on short-term severe treatment toxicity was similar with upfront surgery (OR 2.03, 95%CI 1.22–3.37) and definitive radiotherapy (OR 2.24, 95%CI 1.18–4.27) Patients with sarcopenia are more than twice as likely to suffer a short-term treatment-related toxicity when undergoing curative-intent HNC treatment.
Description
Citation
Citation to related work
Wiley
Has part
Head & Neck, Vol. 46, Iss. 6
ADA compliance
Embedded videos
License
Attribution-NonCommercial-NoDerivs CC BY-NC-ND